Introduction
Lyme borreliosis is the most common infectious disease in Northern Europe carried by ticks in the genus Ixodes. The disease is caused by spirochetes of the genus Borrelia burgdorferi sensu lato, whereas in Europe they are usually strains of B. burgdorferi sensu stricto, B. garinii and B. afzelii. The strains of B. spielmanii and B. bavariensis also play their role in the disease spread [1] . Ticks which primarily feed on wild animals' blood become vectors of Borrelia spirochetes. When these ticks bite people, they transfer spirochetes to their bodies. According to the data published by the National Institute of Public Health -National Institute of Hygiene (Laboratory for Monitoring and Analyzing Epidemiological Situations), the incidence of Lyme borreliosis in Poland is constantly increasing. In 2016, 21 220 new cases were reported (a growth by 55.7% compared to the year 2015, when 13 624 cases were reported) [2] . The clinical manifestations of Lyme borreliosis may include skin, joint, neurological or cardiological changes. According to the recommendations by the Polish Society of Epidemiologists and Doctors of Infectious Diseases [1] , the diagnosis of Lyme borreliosis is based on clinical symptoms, out of which the most characteristic one is migratory erythema (Erythema migrans).
When the migratory erythema appears after a tick bite or following exposure period in endemic areas, it is a sufficient condition to make a diagnosis and introduce an antibiotic therapy. Then, additional serological diagnosis is not recommended. However, if erythema does not develop, but symptoms of disseminated Lyme borreliosis do (Borrelial lymphoma, Neuroboreliosis, Lyme arthritis, Acrodermatitis chronica athrophicans have been recognised in patients with erythema multiforme, then serological tests for IgG and IgM anti-Borrelia antibodies are needed. According to the two-stage diagnostic protocol in Poland [1, 3] , the first test is a highly sensitive ELISA immunoassay. The test should be performed not earlier than 4 weeks after the tick bite. Positive or limit score ELISA results require confirmation by an independent, highly specific Western blot. In the classic case of B. burgdorferi infection, the IgM antibodies appear early to target specific spirochyma proteins. After about 2 weeks after the appearance of IgM antibodies, seroconversion occurs and antibodies of the IgG class appear. In the case of active Lyme borreliosis, an increase in IgG antibody titer is visible with time.
IgM antibodies, which are most often considered to be early-onset markers, can in many cases be permanent and persist for several years after successful treatment. They are most often seen in patients who have been rapidly treated (before seroconversion). Long-term persistence of IgM antibodies does not indicate a need for continued treatment in asymptomatic patients. Antigens in the IgG class can persist in the patient's blood even for the rest of their lives, with a slight downward trend. The best and currently the only proof of the effectiveness of the antibiotic therapy is the remission of clinical symptoms. Unfortunately, ELISA and Western blot tests are often repeated by the patient who has finished therapy, which is a mistake. It should be remembered that antibodies can be present in human serum for many years, so their persistence or even a slight growth does not indicate failure of treatment [1] .
Aim of the study
One of the problems encountered in the Lyme borreliosis diagnosis is the lack of a sensitive and a specific marker of the disease activity to assess the effectiveness of treatment. The ideal marker should react flexibly to infection, i.e. it should appear rapidly after infection in the patient's serum and rapidly disappear after successful treatment. The following paper presents an analysis of available literature describing the possibility of a quantitative measurement of levels of antibody against B. burgdorferi VlsE / C6 protein in monitoring the activity and efficacy of Lyme borreliosis treatment.
Role of VlsE in the pathogenesis of Lyme borreliosis
VlsE (a variable major protein (VMP)-like sequence, Expressed) is a lipoprotein of mass 36 kDa occurring on the surface of the outer cell wall of human pathogenic Borrelia spirochetes. The VlsE lipoprotein expression cassette is located in locus vls and consists of 6 variable regions (VRs) alternating with 7 regions of low variability (IR) [4] . It is believed that a continuous recombination in highly variable regions significantly impedes an effective response from the host immune system, which leads to a development of chronic infection and the survival of spirochetes in mammals [5] . Also, crystallographic analysis of recombinant VlsE showed that the variable domains (VRs) partially override the conservative ones (IR), which further hinders the achievement of effective host immune responses [6] .
As it was demonstrated by mouse models, VlsE variable domain (VR) recombination occurs only in vivo [7] . At the same time, no changes have been observed in the amino acid sequence of variable regions in in vitro spirochaetes and those isolated from the infected ticks. Moreover, in the spirochetes kept in such conditions, the level of expression of the VlsE protein decreases in time. A transfer of bacteria from the tick to a warm-blooded host causes significant changes in the expression of bacterial genes. So far, it has not been possible to identify the factor that causes an increased expression of VlsE protein in mammals [4] . It seems that the key role in spirochete survival in the host, which was also shown in mouse models, is the loss of plasmid lp28-1 encoding the sequence of the expressed VlsE protein, which results in a significant decrease in infectivity [8, 9] . As Rogovskyy et al. indicate, the variability of VlsE protein is an essential factor for Borrelia burgdorferi reinfection [10] . The results obtained by the researchers confirm the key role of VlsE in avoiding the host's immune response.
Role of VlsE protein in diagnostics of Lyme borreliosis
Despite the presence of variable regions (VR) and tertiary protein conformation, which partially overrides the invariant regions [IR] , the VlsE protein exhibits high immunogenicity and is therefore commonly used in serological diagnostics of Lyme borreliosis. As mentioned above, this protein is strongly expressed only in in vivo conditions [7] , thus, the only way to obtain the right antigen for the construction of diagnostic tests is to rely on genetic engineering. As demonstrated in several independent studies [11, 12] , the enrichment of classical diagnostic Borrelia burgdorferi s.l. tests with recombinant VlsE protein significantly increases the sensitivity of the test. In Schulte-Spechtel et al. study, sensitivity increases from 63.8% to 86.1% without loss of specificity [12] . The VlsE protein itself as an antigen also displays the highest diagnostic sensitivity among other Borrelia burgdorferi s.l. antigens used in diagnostic tests [11, 13] .
VlsE has been proved to be the most sensitive marker for the IgG antibody class. Its prevalence in patients with early Lyme borreliosis symptoms ranges from 20% to 50%, increasing to 70% -90% in second-stage patients and reaching 100% in patients with chronic Lyme borreliosis (the third phase) [13] . Further, studies have shown that these invariant (IR) VlsE regions induce a strong immune response in mammals [14] . Then, particular importance is attributed to the invariant region of IR6, often referred to in literature as C6.
C6 in diagnostics of Lyme borreliosis
Out of all 6 invariant regions [IR] of VlsE (IR1-IR6), the most prominent, despite a fairly tight curtain by variable regions (VR), is the IR6, also known as region C6 [6] . Therefore, it is precisely C6 that appears to be the most commonly recognized antibody, the invariant (IR) epitope of the VlsE protein [15, 16] . As Embers et al. showed in a study on 37 patients with a clinically confirmed Lyme borreliosis, the most commonly recognized VlsE epitope is IR6 (C6) (78% of the patients with LB). The N-and C-terminal domains of VlsE were recognized in fewer than 40% of the samples and IR2 or IR4 fragments in fewer than 12% of the samples. What was also surprising was that only 15 patients observed reactions with C6, but not with full recombinant VlsE. According to the authors, in the full VlsE molecule used in the diagnostic tests, the C6 epitope is well covered by variable regions, and it is the variable regions of the protein surface that are responsible for the positive results [17] . Attention has also been paid to the possibility of using C6 in diagnostics of early Lyme borreliosis. In studies by Zajkowska et al. [18] , in the group of patients with migratory erythema, positive or limit score results in C6 protein test were found in 61% of the patients, whereas in the Borrelia IgM recombinant (OspC, ip41 -B. afzelii, B. garinii) test, positive results were obtained in 33% of those tested, and in Borrelia IgG recombinant (OspC, ip41 -B. afzelii, B. garinii, p18, p100), only in 16% of the persons. Among the patients with chronic Lyme borreliosis, C6 IgG was detected in 84% of the patients with 100% of positive recombinant results for Borrelia IgG. An analogous study of patients in Northern Italy has shown a C6 sensitivity in 63% of the patients with early Lime borreliosis and 100% with late Lyme borreliosis and specificity of 100% [19] .
In the Liang et a.l study, the C6-based test gave a positive result for 74% of the patients with early Lyme borreliosis, 80% -95% of the patients after treatment, and 100% of the patients with Lyme borreliosis. In the control group of patients with other spirochetes, the specificity of C6 antigen was 99% [14] . According to Johnsson, in early (acute) Lyme borreliosis, the C6 peptide test increases the diagnostic sensitivity to 60% at this stage of the disease [20] . C6 antigen has also been evaluated as an effective marker for the diagnosis of neuroboreliosis. Assuming that highly pathogenic strains that cause neuroborreliosis in Europe are highly heterogeneous, Fingerle et al., have used a conservative and immunogenic C6 peptide epitope to detect IgG antibodies in early neuroborreliosis. Out of the 36 persons, 34 were positive and 2 were questionable [21] . Similarly, in the studies by Stanek et al. covering 25 patients with neuroborreliosis, the highest sensitivity and specificity was obtained in studies using the peptide IR6 VlsE as an antigen [22] . Also, van Burgel et al. assess C6-based tests as suitable for the routine diagnosis of patients with suspected neuroboreliosis [23] .
The analysis of the above work indicates that the use of C6 antigen in examining patients with early Lyme borreliosis enables getting a positive result faster in those infected with Borrelia burgdorferi s.l., especially in patients with atypical symptoms and without erythema.
C6 as a marker of disease activity and treatment efficacy
In recent years, there have appeared numerous publications suggesting that quantitative IgG class antibody marking can become a helpful tool in identifying VlsE / C6 antigen and monitoring the disease activity. Unlike the other IgG antibodies, anti-VlsE / C6 disappear relatively quickly after the antibiotic therapy is introduced, which prompted researchers to think of monitoring them in order to assess the effectiveness of the treatment. In one of the first publications on this subject, Philipp et al. examined antibody titers against C6 in rhesus monkeys and dogs infected with Borrelia [24] . The study included 7 adult rhesus, in whom there was observed a rise of anti-C6 IgG antibody titer for 12 weeks after the infection to the antibiotic therapy. In 6 out of 7 of the rhesus, a decrease in anti-C6 IgG antibody levels was observed during 9-weeks antibiotic therapy until their total disappearance 13 weeks after the end (the 34 week after infection).
In the same study, anti-C6 IgG antibody titers were observed in 8 dogs infected with Borrelia spirochaete, 4 of which were treated with antibiotics, while the treatment of the others was postponed over time. In the group of the treated dogs, the level of test antibodies was reduced until they disappeared completely several weeks after treatment. At the same time, in the group of untreated dogs, anti-C6 IgG antibodies reached a high level that persisted throughout the study period. In another study, Levy et al. identified 68 infected dogs, 53 of which received treatment, whereas the treatment of further 15 was postponed over time. Then, the level of anti-C6 antibody was measured at the time of therapy initiation as well as after 3, 6, and 12 months after its beginning. The dogs are divided into 2 groups. The first group included individuals with a pre-high level of anti-C6 IgG (30 individuals) and the other one with a relatively low level (23 individuals).
In the first group, a significant decrease in anti-C6 IgG antibodies was observed in relation to the baseline level. In the other, a decrease was noticeable, but it was not so spectacular. No significant change in anti-C6 IgG titre was observed in the untreated dogs [25] . After 1-6 months, all tested patients were seronegative for anti-VlsE / C6 IgG antibodies, including symptom remission [26] . Another study [27] assessed the possibility of using anti-C6 IgG antibodies to evaluate patients with the so called post Lyme syndrome. Patients selected for the study had a well documented Lyme borreliosis, including chronic muscular and neurological symptoms. They were then enrolled in a double-blind trials. Samples were collected twice, at the start of the treatment and 6 months later. In this study, there was no correlation between the decrease in anti-C6 IgG antibody levels and the treatment or disappearance of clinical symptoms. Simultaneously, anti-C6 IgG antibodies were noted in lower titres and less frequently in patients with myelodysplastic syndrome, than in patients with active Lyme borreliosis. Despite this, the authors of the publication evaluate the diagnostic value of anti-C6 IgG antibodies in patients with a syndrome as low.
Conclusions
Rich scientific literature on lipoprotein VlsE allows to treat this antigen as a well-studied marker of confirmed significance in the diagnosis of Lyme borreliosis. Particular attention has been paid in recent years to examining the significance of antibody levels against the unchanged IR6 fragment of the VlsE protein. VlsE / C6 antigen has proven to be a significant marker in the diagnosis of early Lyme borreliosis, and appears to meet the conditions of an effective marker for monitoring efficacy. It is also interesting to use the VlsE / C6 marker in optimizing the current strategy for diagnosing Lyme borreliosis, but this matter requires more research.
Basing on available publications, it would seem reasonable to suggest a strategy of a quantitative assessment of anti-VlsE / C6 anti-VlsE / C6 antibody levels in monitoring the efficacy of treating patients with early Lyme borreliosis, through examination performed at three stages -first before or at the time of the introduction of antibiotic therapy, and then another two -6 and 12 months after the treatment. Disappearance of clinical symptoms combined with a decrease in anti-VlsE / C6 IgG antibody titer will testify about the success of antibiotic therapy. For now, the anti-VlsE / C6 IgG level test to assess the activity of the disease is devoid of a scientific basis. As of today, the VlsE / C6 test is not included in any recognition criteria in diagnosis of Lyme borreliosis. It remains just an additional tool and requires further research.
